Mitral Valve Degeneration

Mitral valve degeneration, more precisely known as myxomatous mitral valve disease, is a progressive degenerative condition affecting the mitral valve of the heart in dogs. The mitral valve is a two-leaflet structure positioned between the left atrium and left ventricle that functions to ensure blood flows in one direction during the cardiac cycle. When this valve degenerates, its leaflets become thickened, irregular, and unable to close properly, allowing blood to leak backward from the ventricle into the atrium during each contraction of the heart.

This condition represents the single most common acquired cardiac disease in dogs, accounting for approximately 75 percent of all canine heart disease cases seen in veterinary practice. The prevalence of mitral valve degeneration increases dramatically with age, and studies have estimated that by ten years of age, approximately one-third of all dogs have some degree of mitral valve pathology detectable on examination. Small breed dogs are disproportionately affected compared to large breed dogs, though the condition can develop in dogs of any size.

The pathological process underlying myxomatous mitral valve disease involves progressive deposition of glycosaminoglycans and proteoglycans within the valve tissue, replacing the normal collagen and elastin architecture of the valve leaflets. This myxomatous transformation causes the valve leaflets to become progressively thickened, elongated, and nodular. The chordae tendineae, the fibrous cords that anchor the valve leaflets to the papillary muscles within the ventricle, may also undergo myxomatous degeneration, becoming weakened and prone to stretching or rupture.

The backward leakage of blood through the incompetent mitral valve, known as mitral regurgitation, triggers a cascade of compensatory responses in the heart and circulatory system. Over time, the left atrium enlarges to accommodate the regurgitant blood volume, and the left ventricle undergoes eccentric hypertrophy as it works harder to maintain adequate forward blood flow. These compensatory changes can maintain the dog in a clinically stable state for months to years, but as the disease progresses and compensatory mechanisms are overwhelmed, congestive heart failure develops.

The exact underlying cause of myxomatous mitral valve degeneration in dogs has not been definitively established, but the condition is understood to result from a complex interplay of genetic predisposition, age-related changes, and biomechanical factors affecting the valve tissue. The strong breed predisposition observed in certain small breed dogs provides compelling evidence for a significant genetic component in the disease's etiology.

Genetic studies, particularly in Cavalier King Charles Spaniels, have demonstrated that myxomatous mitral valve disease follows a polygenic inheritance pattern, meaning that multiple genes contribute to disease susceptibility. Research has identified several chromosomal regions associated with disease risk in this breed, and the heritability of mitral valve disease has been estimated at approximately 60 percent in Cavalier King Charles Spaniels. Breeding programs that select against early-onset mitral valve disease have shown some success in reducing disease prevalence in offspring.

Age represents a fundamental risk factor for mitral valve degeneration, with the prevalence and severity of disease increasing progressively as dogs grow older. The degenerative process appears to be related to cumulative mechanical stress and wear on the valve tissue over the course of a dog's lifetime. Hemodynamic forces acting on the valve leaflets during each cardiac cycle contribute to gradual breakdown of the valve's structural integrity, with millions of opening and closing cycles placing continuous strain on the valve components.

Body size has a well-documented inverse relationship with the risk of developing myxomatous mitral valve disease. Small breed dogs weighing less than 20 kilograms are significantly more likely to develop the condition compared to large and giant breed dogs. The reasons for this size-related predisposition are not entirely clear but may relate to differences in valve geometry, hemodynamic forces, extracellular matrix composition, or genetic factors that correlate with body size. Male dogs appear to develop the condition earlier and more frequently than female dogs, suggesting a sex-linked component to disease susceptibility.

Serotonin signaling pathways have been implicated in the pathogenesis of myxomatous valve degeneration based on research showing altered serotonin metabolism in affected valve tissue. Elevated levels of serotonin and its metabolites have been detected in diseased mitral valve tissue, and serotonin has been shown to promote the proliferation of valve interstitial cells and the production of extracellular matrix components associated with myxomatous degeneration. This line of research has suggested potential therapeutic targets, though clinical applications remain under investigation.

Myxomatous mitral valve disease in dogs follows a well-characterized progression that has been formalized into a staging system by the American College of Veterinary Internal Medicine. This staging system, known as the ACVIM consensus staging, classifies the disease into four stages designated A through D, providing a standardized framework for guiding monitoring frequency, treatment decisions, and prognostic discussions with owners.

Stage A identifies dogs that are at high risk for developing myxomatous mitral valve disease but do not yet have any structural heart changes or clinical signs. This stage encompasses breeds known to be predisposed to the condition, such as Cavalier King Charles Spaniels and Dachshunds. Dogs in Stage A have no detectable heart murmur and no echocardiographic evidence of valvular abnormality. Management at this stage focuses on awareness, regular veterinary screening, and in some breeds, responsible breeding practices that select against early-onset disease.

Stage B encompasses dogs that have structural evidence of mitral valve disease, typically manifested as a heart murmur and echocardiographic changes, but have not yet developed clinical signs of heart failure. This stage is subdivided into B1 and B2 based on the degree of cardiac remodeling. Stage B1 dogs have a murmur but no significant cardiac chamber enlargement on imaging, while Stage B2 dogs demonstrate left atrial and left ventricular enlargement indicating hemodynamically significant mitral regurgitation. The landmark EPIC trial demonstrated that treatment with pimobendan in Stage B2 dogs significantly delays the onset of congestive heart failure.

Stage C designates dogs that have developed clinical signs of congestive heart failure attributable to myxomatous mitral valve disease. These dogs may present with cough, increased respiratory rate and effort, exercise intolerance, and in some cases pulmonary edema. Stage C is further categorized based on whether the dog is experiencing an acute heart failure crisis requiring hospitalization or is in a stable compensated state manageable with outpatient medications. Aggressive medical therapy is the cornerstone of management at this stage.

Stage D represents end-stage disease in which clinical signs of congestive heart failure persist despite maximal standard medical therapy. Dogs in Stage D are considered refractory to treatment and require escalation of therapy with additional medications, dose adjustments, or consideration of surgical intervention where available. This stage carries the most guarded prognosis, and quality of life discussions become increasingly important as the disease approaches its terminal phase.

The clinical signs of myxomatous mitral valve disease in dogs vary considerably depending on the stage of disease and the degree of hemodynamic compromise present. Many dogs remain asymptomatic for extended periods despite having detectable valve pathology, and the first indication of disease is often the incidental discovery of a heart murmur during a routine veterinary examination.

The characteristic heart murmur of mitral valve degeneration is a systolic murmur heard most prominently over the left apex of the heart. This murmur is produced by the turbulent flow of blood regurgitating backward through the incompetent mitral valve during ventricular contraction. The murmur is typically graded on a scale of I to VI, with higher grades generally corresponding to greater degrees of mitral regurgitation, though the correlation between murmur intensity and disease severity is not always consistent.

Coughing is one of the most commonly reported clinical signs in dogs with advancing mitral valve disease and may result from multiple mechanisms. Left atrial enlargement can compress the left main stem bronchus, producing a mechanical cough that may occur regardless of whether pulmonary edema is present. As the disease progresses to congestive heart failure, pulmonary edema develops as fluid accumulates in the lung tissue due to elevated pulmonary venous pressures, producing a cough that may be more productive and associated with increased respiratory effort. Distinguishing between cough caused by airway compression and cough caused by pulmonary edema is clinically important because the causes require different therapeutic approaches.

Exercise intolerance develops as the heart becomes progressively less able to maintain adequate cardiac output to meet the metabolic demands of physical activity. Owners may notice that their dog tires more quickly during walks, is reluctant to climb stairs, or shows increased respiratory effort after activities that were previously well tolerated. In some cases, dogs may experience syncope, or fainting episodes, during exertion or excitement due to transient inadequacy of cerebral blood flow or cardiac arrhythmias.

As congestive heart failure progresses, respiratory signs become more prominent and may include tachypnea, orthopnea characterized by difficulty breathing when lying down, and restlessness at night due to respiratory discomfort. Abdominal distension from ascites may develop if right-sided heart failure accompanies the left-sided failure. Weight loss and muscle wasting, collectively termed cardiac cachexia, can occur in advanced disease as chronic activation of neurohormonal systems and inflammatory pathways contribute to metabolic derangement.

Diagnosis of myxomatous mitral valve disease relies on a combination of physical examination findings, diagnostic imaging, and ancillary tests that together establish the presence and severity of the condition. Early detection and accurate staging are essential for implementing appropriate monitoring schedules and initiating treatment at the optimal time to maximize the benefit of available therapies.

Physical examination provides the initial evidence of mitral valve disease in most cases. Cardiac auscultation revealing a left apical systolic murmur is the hallmark finding, and experienced clinicians can often estimate disease severity based on murmur characteristics, heart rate, respiratory rate, and the presence or absence of adventitious lung sounds. However, physical examination alone is insufficient for accurate disease staging, and advanced imaging is required to assess the degree of cardiac remodeling and hemodynamic compromise.

Echocardiography is the cornerstone diagnostic modality for evaluating myxomatous mitral valve disease in dogs. Two-dimensional echocardiography allows visualization of the thickened, prolapsing mitral valve leaflets and measurement of cardiac chamber dimensions, including left atrial and left ventricular size. Doppler echocardiography enables assessment of the severity of mitral regurgitation by visualizing and quantifying the regurgitant jet. Specific echocardiographic parameters, including the left atrial to aortic root ratio and normalized left ventricular internal diameter in diastole, are used to determine whether cardiac remodeling has reached the threshold that defines Stage B2 disease and qualifies the dog for treatment initiation.

Thoracic radiography provides complementary information about cardiac size, pulmonary vascular patterns, and the presence or absence of pulmonary edema. The vertebral heart score, a standardized radiographic measurement of cardiac silhouette size, is used to objectively track changes in heart size over time. Radiographs are particularly valuable for detecting pulmonary edema in dogs presenting with respiratory signs and for monitoring the response to diuretic therapy in dogs with congestive heart failure.

Cardiac biomarker testing has become increasingly integrated into the diagnostic and monitoring approach for canine mitral valve disease. Circulating concentrations of cardiac troponin I and N-terminal pro-B-type natriuretic peptide provide objective biochemical indicators of myocardial injury and volume overload, respectively. NT-proBNP testing can help distinguish cardiac from non-cardiac causes of respiratory signs and may assist in identifying dogs approaching the threshold for treatment initiation. Serial biomarker measurements can supplement imaging in tracking disease progression over time.

Medical management of myxomatous mitral valve disease in dogs has been significantly refined over the past two decades through landmark clinical trials that have established evidence-based treatment protocols for each stage of the disease. The goal of medical therapy is to alleviate clinical signs, slow disease progression, maintain quality of life, and extend survival time for affected dogs.

Pimobendan is a critically important medication in the management of canine mitral valve disease, functioning as both a positive inotrope that strengthens cardiac contraction and a vasodilator that reduces the workload on the heart. The EPIC trial, published in 2016, demonstrated that initiating pimobendan therapy in preclinical Stage B2 dogs delayed the onset of congestive heart failure by a median of approximately 15 months compared to placebo. This landmark finding established pimobendan as the first medication proven to be beneficial in the preclinical phase of the disease, and it is now considered standard of care for dogs meeting Stage B2 criteria.

Furosemide, a loop diuretic, is the primary medication used to manage the fluid retention and pulmonary edema associated with congestive heart failure in Stage C and Stage D disease. Furosemide promotes renal excretion of sodium and water, reducing the volume overload that drives pulmonary edema formation. The dose is titrated to the minimum effective amount needed to control clinical signs, as excessive diuresis can lead to dehydration, electrolyte imbalances, and activation of compensatory neurohormonal systems that may worsen long-term outcomes. Torasemide, a longer-acting loop diuretic, may be substituted for furosemide in some cases, particularly when more consistent diuretic effect is desired.

Angiotensin-converting enzyme inhibitors, including enalapril and benazepril, are commonly prescribed as part of the multi-drug regimen for dogs in congestive heart failure. These medications block the renin-angiotensin-aldosterone system, reducing vasoconstriction and aldosterone-mediated sodium and water retention. While ACE inhibitors have not demonstrated the same magnitude of benefit as pimobendan in clinical trials, they remain a standard component of heart failure therapy and contribute to neurohormonal modulation that may help slow disease progression.

Spironolactone, an aldosterone receptor antagonist with mild diuretic properties, is increasingly used as an adjunctive therapy in canine mitral valve disease. The DELAY study suggested that spironolactone may provide additional benefit when added to conventional therapy, potentially through its antifibrotic and neurohormonal effects rather than its diuretic action alone. Additional medications that may be employed in more advanced cases include digoxin for rate control in dogs with atrial fibrillation, sildenafil for management of pulmonary hypertension, and antiarrhythmic agents for dogs with significant cardiac rhythm disturbances.

Surgical repair of the mitral valve represents a potentially curative treatment option for dogs with myxomatous mitral valve disease, though its availability remains limited to a small number of specialized veterinary cardiac surgery centers worldwide. Mitral valve repair surgery in dogs is modeled after techniques developed for human cardiac surgery and involves open-heart surgery with cardiopulmonary bypass to allow the surgeon to work on the arrested heart.

The surgical technique most commonly performed for canine mitral valve repair involves a combination of chordal replacement, annuloplasty, and in some cases leaflet modification. Artificial chordae made from expanded polytetrafluoroethylene suture material are placed to replace elongated or ruptured natural chordae tendineae, restoring proper leaflet position and function. An annuloplasty procedure reduces the diameter of the dilated mitral valve annulus, helping the leaflets achieve proper coaptation during ventricular systole. The goal is to restore valve competence and eliminate or substantially reduce mitral regurgitation.

Outcomes of mitral valve repair surgery in dogs have improved dramatically as surgical teams have gained experience and refined their techniques. At experienced centers, perioperative mortality rates have decreased to approximately 5 to 15 percent, and dogs that survive the immediate postoperative period often experience dramatic improvement in cardiac function and clinical status. Many dogs are able to discontinue all cardiac medications within several months following successful surgery, essentially achieving a functional cure of their heart disease.

The decision to pursue mitral valve repair surgery involves careful consideration of multiple factors, including the dog's current disease stage, overall health status, body weight, owner financial resources, and geographic proximity to a surgical center. The procedure is technically demanding, requires sophisticated equipment including a cardiopulmonary bypass machine, and carries inherent risks associated with open-heart surgery and general anesthesia. Current costs for mitral valve repair surgery in dogs typically range from approximately 30,000 to 50,000 dollars or more, placing the procedure beyond the financial reach of many pet owners.

Patient selection is critical for optimizing surgical outcomes. Dogs in Stage C or early Stage D disease who are otherwise in good health are generally considered the best surgical candidates. Dogs with severe cardiac cachexia, advanced renal disease, or other significant comorbidities may be poor candidates due to increased surgical risk. The timing of surgical intervention is also important, as dogs with less severe cardiac remodeling at the time of surgery tend to have better postoperative outcomes and more complete recovery of cardiac function.

Home management of dogs with myxomatous mitral valve disease encompasses dietary considerations, exercise guidelines, environmental modifications, and monitoring practices that collectively contribute to maintaining the best possible quality of life while supporting the effectiveness of medical therapy. Owners play a crucial role in the day-to-day management of their dog's cardiac condition and serve as the primary observers of changes that may signal disease progression.

Dietary management for dogs with mitral valve disease has evolved considerably from earlier recommendations that advocated severe sodium restriction in all stages of the disease. Current guidelines recommend moderate sodium restriction, avoiding high-sodium treats and table scraps while maintaining a palatable, nutritionally complete diet that supports adequate caloric intake. Severe sodium restriction is generally reserved for dogs in congestive heart failure and should be implemented gradually to maintain appetite. Maintaining adequate protein intake is important to help counter cardiac cachexia, and diets enriched with omega-3 fatty acids from marine sources may provide anti-inflammatory and antiarrhythmic benefits.

Exercise recommendations are tailored to the individual dog's disease stage and clinical status. Dogs in preclinical stages with stable cardiac compensation generally benefit from continued moderate exercise, which supports cardiovascular fitness, maintains muscle mass, and contributes to overall quality of life. Owners should allow the dog to set its own pace and avoid forcing strenuous activity. As the disease progresses to heart failure, exercise should be restricted to gentle, low-intensity activities such as short leash walks, with the duration and intensity guided by the dog's tolerance and respiratory status.

Resting respiratory rate monitoring at home is one of the most valuable tools available to owners for early detection of impending or worsening congestive heart failure. Owners are instructed to count their dog's breaths per minute while the dog is resting calmly or sleeping, establishing a baseline value during periods of clinical stability. A sustained increase in resting respiratory rate above 40 breaths per minute, or a significant increase above the individual dog's established baseline, should prompt veterinary evaluation for possible fluid accumulation and heart failure decompensation.

Weight management requires ongoing attention throughout the course of the disease. Obesity increases the cardiovascular workload and should be avoided through appropriate dietary management. Conversely, unintentional weight loss and muscle wasting in the later stages of disease indicate cardiac cachexia and warrant nutritional intervention, potentially including calorie-dense diets and appetite stimulants. Regular body weight and body condition score assessments help track trends that may not be apparent to owners who see their dog daily.

Myxomatous mitral valve disease can give rise to several complications and associated conditions that may significantly impact the clinical course and management of affected dogs. Awareness of these potential complications allows veterinarians and owners to recognize them promptly and implement appropriate interventions.

Chordal rupture is one of the most clinically significant acute complications of chronic mitral valve degeneration. As the chordae tendineae undergo progressive myxomatous degeneration, they become weakened and susceptible to sudden rupture, which can result in acute severe mitral regurgitation and precipitous onset of congestive heart failure. Dogs may present with sudden respiratory distress, and echocardiography reveals a flail mitral valve leaflet with severe regurgitation. This complication requires emergency stabilization with aggressive diuretic therapy, oxygen supplementation, and often the addition or intensification of other cardiac medications.

Atrial fibrillation develops in a proportion of dogs with advanced mitral valve disease as progressive left atrial dilation disrupts the normal electrical conduction pathways within the atrial myocardium. Atrial fibrillation results in a rapid, irregularly irregular heart rate that further compromises cardiac output and accelerates clinical deterioration. Rate control using medications such as diltiazem or digoxin is the primary management strategy, as conversion to normal sinus rhythm is generally not achievable in dogs with significantly enlarged atria.

Pulmonary hypertension is an increasingly recognized complication of advanced mitral valve disease in dogs. Chronic elevation of left atrial pressure leads to secondary increases in pulmonary venous and arterial pressures, which can result in right ventricular dysfunction and biventricular heart failure. Dogs with pulmonary hypertension may exhibit more severe exercise intolerance, syncope, and respiratory signs than would be expected from left-sided disease alone. Echocardiographic estimation of pulmonary artery pressure through measurement of the tricuspid regurgitation jet velocity helps identify this complication, and treatment with sildenafil may be beneficial.

Left atrial tear is a rare but catastrophic complication in which the wall of the severely enlarged left atrium ruptures, allowing blood to escape into the pericardial space and causing cardiac tamponade. This complication presents as acute cardiovascular collapse and carries a very high mortality rate. Some dogs may survive the initial event if pericardiocentesis is performed promptly, but recurrence is common. The risk of atrial tear appears to be highest in small breed dogs with severely dilated left atria, and this complication underscores the importance of ongoing monitoring and timely treatment adjustments in dogs with progressive disease.

The prognosis for dogs diagnosed with myxomatous mitral valve disease spans a wide spectrum depending on the stage at diagnosis, the rate of disease progression, the response to treatment, and individual patient factors. Understanding the expected disease trajectory and factors that influence outcome helps owners prepare for the road ahead and make informed decisions throughout the course of their dog's illness.

Dogs diagnosed in the early preclinical stages of mitral valve disease often enjoy extended periods of good quality of life before the disease progresses to heart failure. Many dogs with Stage B1 disease remain stable for years and may never progress to clinical heart failure during their natural lifespan, particularly if they are diagnosed at an advanced age. Dogs in Stage B2 that are started on pimobendan therapy have a significantly delayed time to heart failure onset compared to those that are not treated, with the median time to heart failure being approximately 1,300 days in treated dogs based on the EPIC trial results.

Once congestive heart failure develops, the prognosis becomes more guarded but remains variable. Median survival times following the onset of congestive heart failure in dogs receiving appropriate medical therapy have been reported at approximately 9 to 12 months in several studies, though individual dogs may survive significantly longer or shorter than this median. Dogs that respond well to initial heart failure therapy and achieve stable compensation tend to have longer survival times compared to those that respond poorly or require frequent treatment escalation.

Several factors have been identified as negative prognostic indicators in dogs with myxomatous mitral valve disease. These include larger left atrial size, higher circulating NT-proBNP concentrations, presence of atrial fibrillation, pulmonary hypertension, presence of syncope, advanced age, lower body weight, and the development of azotemia from renal hypoperfusion or diuretic-related effects. Conversely, factors associated with more favorable outcomes include earlier disease stage at diagnosis, smaller left atrial dimensions, good response to initial medical therapy, and maintenance of normal sinus rhythm.

The overall trajectory of myxomatous mitral valve disease is progressive and ultimately fatal when it reaches the heart failure stage, unless surgical repair is performed. However, with current medical management strategies, many dogs can maintain acceptable to good quality of life for months to years following the onset of heart failure. Regular veterinary follow-up with periodic echocardiographic assessment, radiographic monitoring, and medication adjustments is essential for optimizing outcomes. End-of-life planning should be discussed early so that owners can make thoughtful, informed decisions when quality of life declines to the point where continued treatment is no longer in the dog's best interest.